Eloxatin Information

On January 9, 2004, the Food and Drug Administration announced the approval of Eloxatin (oxaliplatin) injection for the initial treatment of advanced colorectal cancer. Eloxatin is a platinum-based anticancer drug, given in combination with infusional 5-fluorouracil plus leucovorin (5FU/LV). The data showed that, compared to the standard treatment (irinotecan plus 5FU/LCV), the oxaliplatin 5FU/LV regimen was superior in survival, in shrinking tumors, and in delaying tumor regrowth. Eloxatin was previously approved (August 9, 2002) to treat patients with colorectal cancer whose disease has become worse following initial therapy.

Page Last Updated: 07/10/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English